Showing results (841-850 of 1,019) with videos related to

Sort By:
Pageof 102
Clinicoeconomics and Outcomes Research : CEOR|August 16, 2019
Clinical and economic burden of head and neck cancer: a nationwide retrospective cohort study from FranceAntoine Schernberg, Luis Sagaon-Teyssier, Michaël Schwarzinger, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 16, 2019
Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritisAlberto Migliore, Davide Integlia, Giuseppe Pompilio, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 3, 2019
Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in ThailandChaicharn Deerochanawong, Natapong Kosachunhanun, Arvind V Gadekar, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 26, 2022
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast CancerVladislav Berdunov, Steve Millen, Andrew Paramore, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 4, 2021
Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims DatabaseTsugumi Matsumoto, Takanori Tsuchiya, Takahiro Hirano, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 20, 2022
Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)Mihaela Georgiana Musat, Christina Soeun Kwon, Elizabeth Masters, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 15, 2015
Cost and effectiveness of omega-3 fatty acid supplementation in Chinese ICU patients receiving parenteral nutritionGuo Hao Wu, Jian Gao, Chun Yan Ji, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 4, 2025
Early Diagnosis and Timely Terlipressin in Hepatorenal Syndrome Improves Projected Outcomes and Lowers CostJuan F Gallegos-Orozco, Jacqueline G O'Leary, Kapuluru Gautham Reddy, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 4, 2025
Healthcare Utilization and Cost in the Two Years Before Neuromodulation Implantation Among Medicaid Enrollees with Drug-Resistant EpilepsyKathryn Evans, Qian Li, Lu Zhang, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 20, 2021
Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial FibrillationTaru Hallinen, Erkki Soini, Christian Asseburg, et al.
Pageof 102